could

Paribus Embracing DAO transition.

Source Node:
Time Stamp: December 22, 2023 3:09 PM - Modified On: December 22, 2023 - Published By:
Source Cluster:
Republished By Plato

In our journey of developing Paribus, we’ve received a lot of feedback from our community, primarily positive and helpful. But, as is often the case when a small team controls a platform, not everyone agrees with our decisions. At every step, we’ve tried to make the best choices based on the information we had. We’ve always known that, eventually, it would be the community’s turn to take the lead in guiding Paribus. And, as we announced in our recent X-space update, that time is approaching fast with the release of

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:54 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:16 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

Revolutionizing Tourism with Web3: A Landmark Partnership Between Camino Network, DCM Swiss, 1World Online, and Web3-Solutions

Source Node:
Time Stamp: October 12, 2023 12:01 PM - Modified On: October 12, 2023 - Published By:
Source Cluster:
Republished By Plato

In an unprecedented-opportunity-driven move, four innovative companies in the travel and marketing sectors — Camino Network, initiated by Chain4Travel, DCM Swiss, 1World Online, and Web3-Solutions — have come together to announce a landmark partnership. This alliance aims to harness cutting-edge technologies in reshaping the future of travel and tourism experiences and bringing new monetization options and benefits to all ecosystem participants. We are happy to announce that: DCM Swiss and 1World Online are becoming Validators at Camino Network. Web3-Solutions becomes a Regional Partner of DCM: A regional partnership agreement has

The Tightrope of Regulation

Source Node:
Time Stamp: September 26, 2023 7:08 AM - Modified On: September 26, 2023 - Published By:
Source Cluster:
Republished By Plato

In a significant move at the recent G20 meeting in India, the International Monetary Fund (IMF) and the Financial Stability Board (FSB) released a joint paper outlining a framework for the global regulation of cryptocurrencies. While the proposals mostly tread familiar territory, what’s new is their conviction in crypto’s unstoppable growth and success. A flurry of optimism greeted the G20’s endorsement of the report because it advocates that countries don’t ban crypto. Hidden in its text, however, are some worrying signs. For example, on the first page, they state, “Widespread

My Life As A Science Experiment ; Continues

Source Node:
Time Stamp: September 11, 2023 1:04 PM - Modified On: September 11, 2023 - Published By:
Source Cluster:
Republished By Plato

  A year ago Every=Ten of Ten doctors told me with confidence that I would Not get better and could not survive with Kidney function of 4.1% and Creatinine of 12.32. Immediate dialysis leading to a hopeful transplant or; death. I rejected every doctors advice and had this idea that for as long as I can I would reverse engineer manually all the vital functions that kidneys influence. It's 13 months later and I function well using frequent blood tests to tweak my protocol. It's a 24/7 job with 20+

Welcome Renal Warriors

Source Node:
Time Stamp: September 11, 2023 7:58 AM - Modified On: September 11, 2023 - Published By:
Source Cluster:
Republished By Plato

I am a 68 year old man born in Brooklyn, New York and living for decades in Ithaca, NY. I also have 10 years each with homes in @San Ramon, Costa Rica and @Austin, Texas. My present and future dreams are in #Africa and I am setting up a base in @CapeTown, South Africa. #notmytimetodie #supportmymiracle #childofimmigrants #latebloomer. I was told a year ago that I would certainly die if I did not have not follow the standard treatment of care. I rejected both dialysis and a transplant and am

American Picture House Corporate Update

Source Node:
Time Stamp: September 6, 2023 4:28 PM - Modified On: September 6, 2023 - Published By:
Source Cluster:
Republished By Plato

New York, NY, Raleigh, NC, and Los Angeles, CA.  September 6, 2023 – American Picture House Corporation (OTC: APHP), an entertainment company with a focus on producing feature films, limited series, and entertainment enhancing technologies, today provided a corporate update for shareholders. Industry Strikes American Picture House supports the ideals behind the two current industry strikes -- brought by the Writers Guild of America (“WGA”) and the Screen Actors Guild (“SAG”) -- and joins the many reasonable voices urging for a fair and timely resolution. Update on Feature Films -

Starbox Group’s StarboxAI – ViPro Module: Transforming Content Creation

Source Node:
Time Stamp: September 5, 2023 12:41 PM - Modified On: September 5, 2023 - Published By:
Source Cluster:
Republished By Plato

Kuala Lumpur, Malaysia, Sept 5th, 2023 – Starbox Group Holdings Ltd. (Nasdaq: STBX), a dynamic player in cash rebates, digital advertising, and payment solutions, with a vision of leading in artificial intelligence (“AI”) solutions throughout Southeast Asia, is making waves with the launch of its groundbreaking StarboxAI - ViPro module. This innovative module introduces a text-to-video feature set to redefine content creation. The Text-to-Video feature within the StarboxAI - ViPro module is not just an addition; it's a revelation. It empowers content creators to seamlessly transmute textual instructions or scripts

The Collision of Titans: AI and Web3

Source Node:
Time Stamp: September 4, 2023 12:28 PM - Modified On: September 4, 2023 - Published By:
Source Cluster:
Republished By Plato

Over the past decade, two titans have emerged from the tech realm, each promising to redefine the very fabric of our global infrastructure - Artificial Intelligence (AI) and Web3. But what happens when these two forces converge? Are we on the brink of a new digital renaissance or a potentially uncharted dystopia? Consider this: AI is, at its core, the embodiment of advanced logic and decision-making, a machine's ability to "think" and process information in ways eerily similar to humans. It's no longer just about algorithms; it's about creating synthetic